Interspecies prediction of pharmacokinetics and tissue distribution of doxorubicin by physiologically‐based pharmacokinetic modeling
Biopharmaceutics & Drug Disposition · 2020-04 · 41 (4-5) · 192-205
DOI: 10.1002/bdd.2229 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biopharmaceutics & Drug Disposition, online erschienen am 16.05.2020. Verfasst von Jong Bong Lee und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, NJ, 08854, USA. Hauptthemen laut MEDLINE: Models, Biological. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 86 Literaturangaben. Gefördert von: Celgene Corporation, Celgene.
Abstract (Originalsprache)
The aim of the study was to develop a physiologically‐based pharmacokinetic (PBPK) model to describe and predict whole‐body disposition of doxorubicin following intravenous administration. The PBPK model was established using previously published data in mice and included 10 tissue compartments: lungs, heart, brain, muscle, kidneys, pancreas, intestine, liver, spleen, adipose tissue, and plasma. Individual tissues were described by either perfusion‐limited or permeability‐limited models. All parameters were simultaneously estimated and the final model was able to describe murine data with good precision. The model was used for predicting doxorubicin disposition in rats, rabbits, dogs, and humans using interspecies scaling approaches and was qualified using plasma and tissue observed data. Reasonable prediction of the plasma pharmacokinetics and tissue distribution was achieved across all species. In conclusion, the PBPK model developed based on a rich dataset obtained from mice, was able to reasonably predict the disposition of doxorubicin in other preclinical species and humans. Applicability of the model for special populations, such as patients with hepatic impairment, was also demonstrated. The proposed model will be a valuable tool for optimization of exposure profiles of doxorubicin in human patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, NJ, 08854, USA.
- Translational Development and Clinical Pharmacology, Celgene Corporation, NJ, 07920, USA.
- Center of Excellence for Pharmaceutical Translational Research and Education, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, NJ, 08854, USA.
- College of Pharmacy, Daegu Catholic University, Gyeongsan, Republic of Korea, 38430.
ORCID-Profile: Leonid Kagan
Förderung
- Celgene Corporation
- Celgene
Zitieren
APA
Lee, J. B., Zhou, S., Chiang, M., Zang, X., Kim, T. H., & Kagan, L. (2020). Interspecies prediction of pharmacokinetics and tissue distribution of doxorubicin by physiologically‐based pharmacokinetic modeling. Biopharmaceutics & Drug Disposition, 41(4-5), 192-205. https://doi.org/10.1002/bdd.2229
Vancouver
Lee JB, Zhou S, Chiang M, Zang X, Kim TH, Kagan L. Interspecies prediction of pharmacokinetics and tissue distribution of doxorubicin by physiologically‐based pharmacokinetic modeling. Biopharmaceutics & Drug Disposition. 2020;41(4-5):192-205. doi:10.1002/bdd.2229
BibTeX
@article{Lee2020,
author = {Lee, Jong Bong and Zhou, Simon and Chiang, Manting and Zang, Xiaowei and Kim, Tae Hwan and Kagan, Leonid},
title = {Interspecies prediction of pharmacokinetics and tissue distribution of doxorubicin by physiologically‐based pharmacokinetic modeling},
journal = {Biopharmaceutics & Drug Disposition},
year = {2020},
volume = {41},
number = {4-5},
pages = {192--205},
doi = {10.1002/bdd.2229}
}
EUVIMED